Document Type : Review Article


1 Central Administration of Drug Control, Egyptian Drug Authority, El Mansoria, Egypt

2 Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt

3 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

4 School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, New Administrative Capital, Cairo, Egypt


This review explores the significant advancements in topical skin cancer treatments, particularly focusing on the revolutionary role of nanotechnology in addressing the limitations found in traditional therapeutic methods. This comprehensive evaluation delves into the innovative development and clinical efficacy of cutting-edge nanocarrier platforms, notably those encapsulating Imiquimod. These platforms are specifically designed to enhance the delivery and performance of topical agents in the fight against nonmelanoma skin cancers, a prevalent concern in dermatological oncology.

The analysis methodically confronts the obstacles inherent to conventional skin cancer treatments by providing an in-depth examination of how nanotechnology-based platforms improve drug bioavailability, facilitate deeper skin penetration, and boost patient compliance with treatment protocols. This shift towards nanotechnology signifies a paradigm shift towards more patient-oriented and efficacious treatment modalities, offering a precise, targeted, and minimally invasive approach.

Moreover, the review not only underscoresillustrate the potential the transformative potential of nanotechnology in dermatological applications but alsoand heralds a significant progression in the field of topical oncological treatments field. By highlighting the advancements facilitated by nanocarrier systems.

This shows that, with such enhanced treatments of skin cancer, there shall be a shift from a patient-centered approach that minimizes interruptions to the regimen and hence reduces recurrence rates, which marks the first foremost goal. In this way, not only will more easily accessible and effective therapies be facilitated, but also, in proportion to a better quality of life, that is kept to the minimum of patient distress.